A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (NCT05060016)
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).
🩺 Plain-English Summary (8th-Grade Level)
The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2 * evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (80 Sites)
Showing the first 25 of 80 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Christiana Care Health Services — Newark, Delaware
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute — Atlanta, Georgia
- University of Iowa — Iowa City, Iowa
- Dana Farber - Harvard Cancer Center — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- Dartmouth Hitchcock Medical Center — Hanover, New Hampshire
- Duke University Medical Center — Durham, North Carolina
- Wake Forest Baptist Comprehensive Cancer Research Center — Winston-Salem, North Carolina
- Oncology Hematology Care Inc — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- University of Pittsburgh Medical Center Cancer Pavillion — Pittsburgh, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- West Virginia University Health Sciences Center — Morgantown, West Virginia
- Universitaetsklinikum Krems — Krems,
- Landeskrankenhaus Salzburg — Salzburg,
- Universitair Ziekenhuis Gent — Ghent,
- Grand Hopital de Charleroi - Site Saint Joseph — Gilly,
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven,
- Rigshospitalet — Copenhagen,
- Centre Hospitalier Universitaire Nord — Marseille,
- Institut Curie — Paris,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed/Refractory Small Cell Lung Cancer
Explore by condition: All Relapsed/Refractory Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.